Ulobetasol
| Clinical data | |
|---|---|
| Trade names | Ultravate |
| Other names | (6S,8S,9S,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one, halobetasol (USAN US) |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601060 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H27ClF2O4 |
| Molar mass | 428.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Ulobetasol (INN) or halobetasol (USAN) is a corticosteroid used to treat psoriasis. It is a class I corticosteroid under the US classification and a group III corticosteroid under international classification, the most potent group of such drugs.
Ulobetasol propionate is usually supplied as a 0.05% topical cream. Ulobetasol is the strongest topical steroid available. It is also sold with tazarotene with 0.01% halobetasol and 0.045% tazarotene as a lotion branded as Duobrii (Bausch Health).
It is available as a generic medication.